Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Q2 2024 Earnings Presentation
25 slides from Acadia Pharmaceuticals's earnings presentation, Aug 6, 2024
Slide 1: Second Quarter 2024 Earnings Call
Second Quarter 2024 Earnings Call August 6, 2024
Slide 2: Call Agenda
Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Steve Davis | President and Chief Executive Officer Commercial Update Brendan Teehan | Chief Operating Officer, Head of Commercial R&D Update Elizabeth Thompson | Executive Vic
Slide 3: Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would
Slide 4: Opening Remarks
Opening Remarks Steve Davis, President and Chief Executive Officer 4
Slide 5: Acadia Investment Thesis
Acadia Investment Thesis Two successful Two late-stage assets with Financial commercial franchises strong early-stage pipeline strength $242.0M in 2Q 2024 revenues Ongoing P3 trial of ACP-101 in 46% YoY revenue growth • NUPLAZID for hallucinations Prader-Willi syndrome in 2Q24 and delusions associat
Slide 6: Commercial Product Highlights
Commercial Product Highlights DAYBUE NUPLAZID • 2Q net product sales of $84.6M, 11% sequential • 2Q net product sales of $157.4 million, 11% year- growth over-year growth • Sequential improvement in weekly rate of new • Growth driven by real-world evidence studies and patient starts and lower rate o
Slide 7: Deep CNS and Rare Disease Pipeline
Deep CNS and Rare Disease Pipeline Program Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed NUPLAZID® Parkinson’s Disease (pimavanserin) Psychosis DAYBUE Rett Syndrome (trofinetide) Hyperphagia in ACP-1011,2 Prader-Willi Syndrome Alzheimer’s Disease ACP-2042 Psychosis Rett Syndrome; Fragile A
Slide 8: Commercial Update
Commercial Update Brendan Teehan, Chief Operating Officer, Head of Commercial 8
Slide 9: DAYBUE in 2024
DAYBUE in 2024 2Q sequential performance: Sizeable future market opportunity: • 12% higher weekly rate of new patient • ~30% of all diagnosed Rett patients in additions the U.S. have initiated treatment by end of 2Q and continuing to grow • 46% lower weekly rate of discontinuations Expanding prescri
Slide 10: Leveraging Real-World Experiences
Leveraging Real-World Experiences IRSF ASCEND Conference, June 2024 Poster Presentations • Assessing experiences with trofinetide for Rett syndrome: interviews with caregivers of patients in LAVENDER , LILAC-1 , and LILAC-2 studies • Real-world benefits and tolerability of trofinetide for the treatm
Slide 11: Long Term DAYBUE Revenue and Value Drivers
Long Term DAYBUE Revenue and Value Drivers Size of • ~1/3 of 5000 diagnosed patients have initiated DAYBUE therapy Opportunity • Believe diagnosed & addressable population can expand to prevalence of 6,000-9,000 Market • Surveyed HCPs state over next 24 months they expect to increase total RXs of Re
Slide 12: Dynamics Supporting Growth in NUPLAZID
Dynamics Supporting Growth in NUPLAZID $157.4M in net product sales in 2Q24, up 11% year-over-year Real-World Evidence1-3 findings: Label Change clarifying: • Reduced mortality when using pimavanserin as • NUPLAZID can be prescribed to treat patients compared to off-label atypical antipsychotics wit
Slide 13: NUPLAZID Growing and Taking Share
NUPLAZID Growing and Taking Share PD and PDP Market 2Q24 vs 1Q24 • PD broader market has stabilized • Ended Q2 with the highest number Carbidopa-Levodopa TRXs 1% of patients on NUPLAZID in the community setting since launch NBRXs for Other APs* -8% • Strong performance among continuing Nuplazid NBRX
Slide 14: Stabilized PD Market Conditions Create Attractive Environment to Launch Consumer Campaign
Stabilized PD Market Conditions Create Attractive Environment to Launch Consumer Campaign Disease State Branded Unaided awareness of hallucinations & delusions in PD market with caregivers and patients is down from a peak of 33% since • Awareness of NUPLAZID stopping DTC advertising in November 2021
Slide 15: R&D Update
R&D Update Elizabeth HZ Thompson, Executive Vice President, Head of Research and Development 15
Slide 16: Prader-Willi Syndrome Opportunity
Prader-Willi Syndrome Opportunity Rare and complex neurobehavioral genetic disorder that often leads to social isolation Hyperphagia is a defining characteristic of Prader-Willi syndrome (PWS) and commonly begins between the ages of 3-8 Hyperphagia is characterized by unrelenting hunger Significant
Slide 17: Ongoing Phase 3 Study of ACP-101 for Hyperphagia in PWS
Ongoing Phase 3 Study of ACP-101 for the Treatment of Hyperphagia in PWS Phase 3 Study Design ACP-101 (Carbetocin) 3.2 mg Trial builds on previous Phase 3 clinical trial experience Double-blind Primary Endpoint: Screening Visit 12 Weeks Change in HQ-CT1 ~170 Subjects 3.2 mg dose was observed to redu
Slide 18: ACP-204 in Alzheimer's Disease Psychosis (ADP)
ACP-204 in Alzheimer's Disease Psychosis (ADP) Strategic goal: expand and extend neuropsychiatry portfolio Target Product Profile Phase 1 Results Mitigate or eliminate QT prolongation No sign of QT prolongation Wide dose range established Explore doses higher than pimavanserin 34 supporting potentia
Slide 19: ACP-204: Phase 2 / Phase 3 Program for the Treatment of ADP
ACP-204: Phase 2 / Phase 3 Program for the Treatment of ADP Phase 2 Two Phase 3 Studies N=318, double-blind, of similar size and design Pimavanserin randomized 1:1:1 experience supports P2 / P3 program ACP-204 (60 mg) 6-week Phase 2 and each Phase 3 ACP-204 (30 mg) treatment ACP-204 (60 mg) period s
Slide 20: Building Body of Evidence around DAYBUE with Presentations and Publications
Building Body of Evidence around DAYBUE with Presentations and Publications LILAC-1 and LILAC-2 LOTUS Open-label extension studies1,2 Real-world observational evidence study3 Long-term treatment continued to improve Found evidence of significant variation in symptoms, without evidence of new safety
Slide 21: Financial Update
Financial Update Mark Schneyer, Chief Financial Officer 21
Slide 22: 2Q24 Financial Highlights
2Q24 Financial Highlights Millions, Except EPS 2Q24 2Q23 YoY Change TOTAL Net Sales $242.0 $165.2 46% NUPLAZID Net Product Sales $157.4 $142.0 11% DAYBUE Net Product Sales $84.6 $23.2 265% R&D $76.2 $58.8 30% SG&A $117.1 $96.0 22% Net Income (Loss) $33.4 $1.1 - EPS $0.20 $0.01 - Year End 2023 Cash B
Slide 23: Updating FY 2024 Financial Guidance
Updating FY 2024 Financial Guidance Prior FY24 Guidance Updated FY24 Guidance NUPLAZID Net Sales $560 - $590 Million $590 - $610 Million NUPLAZID Gross-to-Net 25% - 29% 26% - 28% DAYBUE Net Sales $370 - $420 Million $340 - $370 Million Total Revenue $930 Million - $1.01 Billion $930 - $980 Million R
Slide 24: Building On Our Success
Leverage physician and caregiver real world experience and capitalize on DAYBUE long-term value drivers Build on real-world evidence and favorable label clarification while introducing new DTC campaigns to grow NUPLAZID franchise Building On Bring trofinetide to new markets outside the U.S. includin
Slide 25: Q&A Session
Vana inaeduamnnnannai aneamiaeiaeaanae Q&A Session
ACADIA Pharmaceuticals — Q2 2024 Earnings Presentation on 6ix